FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379283657> ?p ?o ?g. }

• W4379283657 endingPage "e14530" @default.
• W4379283657 startingPage "e14530" @default.
• W4379283657 abstract "e14530 Background: Nowadays, CAR-T cell therapy still faces limited therapeutic efficacy for solid tumors. SIRPγ is known as a ligand for a well-known immune checkpoint molecule CD47. It is distinguished from other members of its family in that it has a very short intracytoplasmic tail and is incapable of transducing signals on its own. Of note, the role of SIRPγ still largely unknown to date. Preliminary data indicated SIRPγ plays a key role in T-cell transendothelial migration and promotes antigen-specific T-cell proliferation. We thus designed a novel SIRPγ-CD28 chimeric receptor comprising the extracellular part of SIRPγ, the transmembrane and intracellular domains of CD28 and used as the co-receptor for a CEA-targeting CAR. Here, we report on the activity of this armed CAR-T with the SIRPγ-CD28 co-receptor in colorectal tumor (CRC) and its anti-tumor efficacy in mice xenograft model. Methods: In vitro luciferase-based cytotoxicity assay were used by coculturing CAR-T and DLD1-CEA CRC cells to assess the activities of CAR-T w/wo the co-receptor. The incubation supernatants were collected for detecting the release of cytokines. In vivo evaluation of the anti-tumor efficacy of CAR-T with the SIRPγ-CD28 co-receptor versus control T cell, and control CAR-T was performed in NOG mice CRC xenograft model. DLD1-CEA cells expressing luciferase reporter were s.c. implanted and T cells were i.v. injected. Anti-tumor efficacy was assessed by in vivo system. Results: CAR-T with the SIRPγ-CD28 co-receptor exhibited specific cytotoxicity only to CEA + CRC cells, and the efficacies of CAR-T w/wo the co-receptor were comparable (88.6% vs 87.8%, p > 0.05). However, cytokines were significantly higher in the CAR-T group with the co-receptor. The levels of IFNγ, IL2 and TNFα in groups of CAR-T w/wo the co-receptor were 72,793.33 vs 19,013.33 pg/ml (p < 0.05), 1834.67 vs 25.15 pg/ml (p < 0.05) and 79.65 vs 0 pg/ml (p < 0.05), respectively. In mice CRC xenografts model, the tumors were totally eliminated in the CAR-T group with the co-receptor at 21 days and lasted until the end of experiment, while the tumor growth was suppressed in the control CAR-T group at first and out-of-control in the end (Table). Conclusions: These preclinical studies demonstrated the potential of SIRPγ-CD28 co-receptor as a novel T cellular activation signals for CAR-T. The armed CAR-T exhibits a fabulous anti-tumor efficacy in CRC and has great potential for applications in other solid tumors. [Table: see text]" @default.
• W4379283657 created "2023-06-05" @default.
• W4379283657 creator A5008087825 @default.
• W4379283657 creator A5014723221 @default.
• W4379283657 creator A5018324670 @default.
• W4379283657 creator A5020659750 @default.
• W4379283657 creator A5021756862 @default.
• W4379283657 creator A5023363049 @default.
• W4379283657 creator A5032803732 @default.
• W4379283657 creator A5035233009 @default.
• W4379283657 creator A5041151640 @default.
• W4379283657 creator A5044154626 @default.
• W4379283657 creator A5058159511 @default.
• W4379283657 creator A5060215503 @default.
• W4379283657 creator A5066778385 @default.
• W4379283657 creator A5067607038 @default.
• W4379283657 creator A5077423550 @default.
• W4379283657 creator A5080234581 @default.
• W4379283657 creator A5082857859 @default.
• W4379283657 creator A5082951115 @default.
• W4379283657 creator A5085353751 @default.
• W4379283657 date "2023-06-01" @default.
• W4379283657 modified "2023-09-25" @default.
• W4379283657 title "Armed CEA CAR-T with a SIRPγ-CD28 chimeric co-receptor to exhibit the enhanced antitumor activity in preclinical study of colorectal cancer." @default.
• W4379283657 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e14530" @default.
• W4379283657 hasPublicationYear "2023" @default.
• W4379283657 type Work @default.
• W4379283657 citedByCount "0" @default.
• W4379283657 crossrefType "journal-article" @default.
• W4379283657 hasAuthorship W4379283657A5008087825 @default.
• W4379283657 hasAuthorship W4379283657A5014723221 @default.
• W4379283657 hasAuthorship W4379283657A5018324670 @default.
• W4379283657 hasAuthorship W4379283657A5020659750 @default.
• W4379283657 hasAuthorship W4379283657A5021756862 @default.
• W4379283657 hasAuthorship W4379283657A5023363049 @default.
• W4379283657 hasAuthorship W4379283657A5032803732 @default.
• W4379283657 hasAuthorship W4379283657A5035233009 @default.
• W4379283657 hasAuthorship W4379283657A5041151640 @default.
• W4379283657 hasAuthorship W4379283657A5044154626 @default.
• W4379283657 hasAuthorship W4379283657A5058159511 @default.
• W4379283657 hasAuthorship W4379283657A5060215503 @default.
• W4379283657 hasAuthorship W4379283657A5066778385 @default.
• W4379283657 hasAuthorship W4379283657A5067607038 @default.
• W4379283657 hasAuthorship W4379283657A5077423550 @default.
• W4379283657 hasAuthorship W4379283657A5080234581 @default.
• W4379283657 hasAuthorship W4379283657A5082857859 @default.
• W4379283657 hasAuthorship W4379283657A5082951115 @default.
• W4379283657 hasAuthorship W4379283657A5085353751 @default.
• W4379283657 hasConcept C121608353 @default.
• W4379283657 hasConcept C126322002 @default.
• W4379283657 hasConcept C148125776 @default.
• W4379283657 hasConcept C150903083 @default.
• W4379283657 hasConcept C154317977 @default.
• W4379283657 hasConcept C170493617 @default.
• W4379283657 hasConcept C185592680 @default.
• W4379283657 hasConcept C202751555 @default.
• W4379283657 hasConcept C203014093 @default.
• W4379283657 hasConcept C207001950 @default.
• W4379283657 hasConcept C2776090121 @default.
• W4379283657 hasConcept C2776107976 @default.
• W4379283657 hasConcept C3875195 @default.
• W4379283657 hasConcept C502942594 @default.
• W4379283657 hasConcept C526805850 @default.
• W4379283657 hasConcept C55493867 @default.
• W4379283657 hasConcept C71924100 @default.
• W4379283657 hasConcept C86803240 @default.
• W4379283657 hasConcept C8891405 @default.
• W4379283657 hasConceptScore W4379283657C121608353 @default.
• W4379283657 hasConceptScore W4379283657C126322002 @default.
• W4379283657 hasConceptScore W4379283657C148125776 @default.
• W4379283657 hasConceptScore W4379283657C150903083 @default.
• W4379283657 hasConceptScore W4379283657C154317977 @default.
• W4379283657 hasConceptScore W4379283657C170493617 @default.
• W4379283657 hasConceptScore W4379283657C185592680 @default.
• W4379283657 hasConceptScore W4379283657C202751555 @default.
• W4379283657 hasConceptScore W4379283657C203014093 @default.
• W4379283657 hasConceptScore W4379283657C207001950 @default.
• W4379283657 hasConceptScore W4379283657C2776090121 @default.
• W4379283657 hasConceptScore W4379283657C2776107976 @default.
• W4379283657 hasConceptScore W4379283657C3875195 @default.
• W4379283657 hasConceptScore W4379283657C502942594 @default.
• W4379283657 hasConceptScore W4379283657C526805850 @default.
• W4379283657 hasConceptScore W4379283657C55493867 @default.
• W4379283657 hasConceptScore W4379283657C71924100 @default.
• W4379283657 hasConceptScore W4379283657C86803240 @default.
• W4379283657 hasConceptScore W4379283657C8891405 @default.
• W4379283657 hasIssue "16_suppl" @default.
• W4379283657 hasLocation W43792836571 @default.
• W4379283657 hasOpenAccess W4379283657 @default.
• W4379283657 hasPrimaryLocation W43792836571 @default.
• W4379283657 hasRelatedWork W1969897672 @default.
• W4379283657 hasRelatedWork W1997025161 @default.
• W4379283657 hasRelatedWork W2060451389 @default.
• W4379283657 hasRelatedWork W2160598672 @default.
• W4379283657 hasRelatedWork W2892125791 @default.
• W4379283657 hasRelatedWork W3099784960 @default.
• W4379283657 hasRelatedWork W3137476328 @default.
• W4379283657 hasRelatedWork W3204012246 @default.

• next